A clinical study on treatment for nonalcoholic steatohepatitis with L-ornithine-L-aspartate
- VernacularTitle:左旋门冬氨酸鸟氨酸治疗非酒精性脂肪性肝炎的临床观察
- Author:
Hekun YIN
;
Qixiang LI
;
Ruhuan XIE
;
Wei ZHOU
;
- Publication Type:Journal Article
- Keywords:
Hepatitis,chronic;
Fatty liver;
L-ornithine-L-aspartate;
Triglycerides
- From:
Chinese Journal of General Practitioners
2003;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study efficacy of L-ornithine-L-aspartate (Hepa-Merz) in treatment for nonalcoholic steatohepatitis (NASH) and its effect on lowering serum level of triglycerine MethodsTotally, 30 patients with nonalcoholic steatohepatitis diagnosed by liver function test, B ultrasound scanning and liver biopsy were treated by intravenous infusion of L ornithine L aspartate (Hepa Merz) 10 g daily for 21 days Activities of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and serum level of triglycerine (TG) were determined for all the cases before and after treatment Results Activities of serum ALT and AST and serum level of TG were restored to normal in 29 (96 7%) and in 28 (93 3%) of 30 patients, respectively, after treatment No serious adverse effects were found during treatment Conclusions L ornithine L aspartate (Hepa Merz) is a safe and effective drug in treatment for nonalcoholic steatohepatitis, and can lower serum level of triglycerine significantly
